FDA Should Require Cardiovascular Outcomes Trials For All Type 2 Diabetes Drugs, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Endocrinologic and Metabolic Drugs Advisory Committee asks the agency to eliminate a degree of risk for all candidates, even if no safety signal emerges from the clinical program.